Please assess the completion status of the following clinical trial:

Trial Title: Influenza Vaccine Post Allogeneic Transplant

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patient Population~  * HSCT recipients who are greater than 60 days post transplant.~ * Age 6 months and older who are greater than 60 days post post allogeneic hematopoietic cell transplant~ * Show neutrophil recovery, platelet count \> 50,000/mm3 (may be transfused), no known disease relapse~ * No history of previous allergic reaction to influenza vaccine, known egg allergy or Guillan-Barre Syndrome~ * No flu vaccine in previous 4 months, no Campath in previous 6 months, no intravenous immune globulin (IVIG) in previous 3 months~* Controls:~  * Age 18 to 50 years~ * No history of previous allergic reaction to influenza vaccine, known egg allergy or Guillan-Barre Syndrome~ * No flu vaccine in previous 4 months

- Gender: ALL
- Minimum Age: 6 Months
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- Participants Receiving 1 Dose of Vaccine (Type: ACTIVE_COMPARATOR): Control group participants (healthy volunteers):~* Age 18 to 50 years~* No history of previous allergic reaction to influenza vaccine, known egg allergy or Guillan-Barre Syndrome~* No flu vaccine in previous 4 months~and/or HSCT recipients who are greater than 60 days post transplant.
- Participants Receiving 2 Doses of Vaccine (Type: ACTIVE_COMPARATOR): Hematopoietic stem cell transplant (HSCT) recipients who are greater than 60 days post transplant.

Based on this trial design, predict the completion outcome and termination type (if applicable).